• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by NovoCure Limited

    4/21/25 7:02:59 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care
    Get the next $NVCR alert in real time by email
    DEFA14A 1 defa-14a2025proxynotice.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ______________________________________________
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. ) 
    ______________________________________________
    Filed by the Registrant ☑Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☑Definitive Additional Materials
    ☐Soliciting Material under § 240.14a-12
    NovoCure Limited
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check the appropriate box):
    ☑No fee required.
    ☐Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
    (1)
    Title of each class of securities to which transaction applies:

    (2)
    Aggregate number of securities to which transaction applies:

    (3)
    Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

    (4)
    Proposed maximum aggregate value of transaction:

    (5)
    Total fee paid:

    ☐Fee paid previously with preliminary materials.
    ☐Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    (1)
    Amount Previously Paid:

    (2)
    Form, Schedule or Registration Statement No.:

    (3)
    Filing Party:

    (4)
    Date Filed:







    Your Vote Counts! NOVOCURE LIMITED SECOND FLOOR, NO. 4 THE FORUM GRENVILLE STREET ST. HELIER E2 4UF JERSEY, CHANNEL ISLANDS NOVOCURE LIMITED 2024 Annual Meeting Vote by June 1, 2025 11:59 PM ET. You invested in NOVOCURE LIMITED and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 4, 2025. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 21, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com. Control #. Smartphone users Point your camera here and vote without entering a control number. Vote in Person at the Meeting* June 4, 2025 9:00 AM ET. NovoCure Limited Second Floor, No. 4 The Forum Grenville Street St. Helier JE2 4UF Jersey, Channel Islands *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.



    novocurelimited_naxp30933x.jpg






    Your Vote Counts! NOVOCURE LIMITED SECOND FLOOR, NO. 4 THE FORUM GRENVILLE STREET ST. HELIER E2 4UF JERSEY, CHANNEL ISLANDS NOVOCURE LIMITED 2024 Annual Meeting Vote by June 2, 2024 11:59 PM ET. You invested in NOVOCURE LIMITED and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 5, 2024. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com. Control #. Smartphone users Point your camera here and vote without entering a control number. Vote in Person at the Meeting* June 5, 2024 9:00 AM ET. NovoCure Limited Second Floor, No. 4 The Forum Grenville Street St. Helier JE2 4UF Jersey, Channel Islands *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.






    novocurelimited_naxp30933xa.jpg




    Vote at www.ProxyVote.com. THIS IS NOT A VOTABLE BALLOT. This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting items Board Recommends. For. 1. Election of Directors. Nominees: 1a. Ashley Cordova 1b. Asaf Danziger 1c. William Doyle 1d. Jeryl Hilleman 1e. David Hung 1f. Kinyip Gabriel Leung 1g. Martin Madden 1h. Allyson Ocean 1i. Timothy Scannell 1j. Kristin Stafford 1k. William Vernon 2. The approval and ratification of the appointment, by the Audit Committee of our Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the Company’s fiscal year ending December 31, 2025. 3. A non-binding advisory vote to approve executive compensation. 4. The approval of our 2025 Employee Share Purchase Plan. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.



    Get the next $NVCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVCR

    DatePrice TargetRatingAnalyst
    7/25/2025$14.50Overweight → Equal Weight
    Wells Fargo
    7/8/2025$30.00Buy
    Ladenburg Thalmann
    12/2/2024$18.00 → $30.00In-line → Outperform
    Evercore ISI
    10/16/2024$24.00 → $30.00Neutral → Buy
    H.C. Wainwright
    11/20/2023$15.00Neutral
    JP Morgan
    8/28/2023$85.00 → $25.00Buy → Neutral
    H.C. Wainwright
    8/8/2023$45.00Neutral → Overweight
    Piper Sandler
    8/4/2023$51.00Outperform
    SVB Securities
    More analyst ratings

    $NVCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $NVCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novocure Appoints Company President Frank Leonard as Chief Executive Officer

    Novocure (NASDAQ:NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. "During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their survivals. Frank has been instrumental in creating Novocure's culture and guiding the organization at critical points, including preparing the company for its first commercial launch and establishing the business functions that continue to

    12/1/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

    Novocure (NASDAQ:NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle, Novocure's Executive Chairman, will take part in a fireside chat at 11:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through t

    11/26/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure to Participate in 2025 Jefferies Global Healthcare Conference

    Novocure (NASDAQ:NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer, will present on behalf of the company at 2:00 p.m. GMT (9:00 a.m. ET). Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event. About Novocure Novocure is a global oncology company work

    11/12/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NovoCure downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded NovoCure from Overweight to Equal Weight and set a new price target of $14.50

    7/25/25 8:59:40 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on NovoCure with a new price target

    Ladenburg Thalmann initiated coverage of NovoCure with a rating of Buy and set a new price target of $30.00

    7/8/25 8:49:22 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    NovoCure upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded NovoCure from In-line to Outperform and set a new price target of $30.00 from $18.00 previously

    12/2/24 6:59:42 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    SEC Filings

    View All

    NovoCure Limited filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NovoCure Ltd (0001645113) (Filer)

    12/1/25 7:01:24 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by NovoCure Limited

    SCHEDULE 13G/A - NovoCure Ltd (0001645113) (Subject)

    11/13/25 7:06:14 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by NovoCure Limited

    10-Q - NovoCure Ltd (0001645113) (Filer)

    10/30/25 7:00:11 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Brackmann Christoph covered exercise/tax liability with 7,033 units of Ordinary Shares, decreasing direct ownership by 5% to 134,117 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    11/4/25 4:10:10 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Paravasthu Mukund covered exercise/tax liability with 3,117 units of Ordinary Shares, decreasing direct ownership by 4% to 80,439 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    11/4/25 4:09:58 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    EVP, Pres., Novocure Oncology Leonard Frank X covered exercise/tax liability with 966 units of Ordinary Shares, decreasing direct ownership by 0.28% to 347,745 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    11/4/25 4:09:29 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Cordova Ashley bought $996,859 worth of Ordinary Shares (81,550 units at $12.22), increasing direct ownership by 23% to 437,569 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    9/8/25 7:10:52 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    7/30/25 4:33:06 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NovoCure Limited

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    7/10/24 1:14:41 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by NovoCure Limited

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    7/8/24 4:32:39 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    2/13/24 5:09:51 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Financials

    Live finance-specific insights

    View All

    Novocure Reports Third Quarter 2025 Financial Results

    Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 Premarket approval application for Tumor Treating Fields therapy use in pancreatic cancer submitted and under substantive review by the U.S. Food and Drug Administration Novocure (NASDAQ:NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic

    10/30/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure to Report Third Quarter 2025 Financial Results

    Novocure (NASDAQ:NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three- and nine-month periods that ended September 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.

    10/1/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure Reports Second Quarter 2025 Financial Results

    Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "With the first half of 2025 complete, I am pleased

    7/24/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Leadership Updates

    Live Leadership Updates

    View All

    Novocure Appoints Company President Frank Leonard as Chief Executive Officer

    Novocure (NASDAQ:NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company. "During his more than 15-year career at Novocure, Frank has led many of our global business operations developing deep expertise in delivering our unique, device-based cancer therapy to patients to extend their survivals. Frank has been instrumental in creating Novocure's culture and guiding the organization at critical points, including preparing the company for its first commercial launch and establishing the business functions that continue to

    12/1/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure Appoints Christoph Brackmann as Chief Financial Officer

    Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product

    10/30/24 7:02:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

    Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

    10/18/24 9:00:00 AM ET
    $ENV
    $LH
    $MASI
    Business Services
    Consumer Discretionary
    Medical Specialities
    Health Care